Adlai Nortye Group vs Taysha Gene Therapies
Taysha Gene Therapies is the larger business, with $9.8m of revenue in fiscal 2025 against $5.0m for Adlai Nortye Group (2.0 times as much). Taysha Gene Therapies grew faster (17.3% against 0.0%). Adlai Nortye Group kept more of each dollar of sales as profit: a net margin of -710.6% against -1115.3%.
| Latest fiscal year | Adlai Nortye GroupANL, 2025 | Taysha Gene TherapiesTSHA, 2025 |
|---|---|---|
| Revenue | $5.0m | $9.8m |
| Revenue growth | 0.0% | 17.3% |
| Net income | −$35.5m | −$109m |
| Operating margin | -714.0% | -1130.6% |
| Net margin | -710.6% | -1115.3% |
| Return on equity | -106.5% | -68.5% |
| Free cash flow | −$33.6m | −$93.8m |
| Cash | $8.1m | $320m |
| Total debt | $24.6m | $50.1m |
| Debt to equity | — | 20.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 99 |
| Market value | $304m | $1.32bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 7 sales | 0 buys, 12 sales |